Ongoing research into predictive biomarkers for anti-TIGIT ICI and the development of anti-TIGIT antibodies with optimal immunologic activity and therapeutic efficacy are critical for advancing TIGIT-targeting therapies in the treatment of ESCC and other cancers. This evidence concerns the gene TIGIT and cancer.